Best Compounded GLP-1 Programs (2026)
Compounded semaglutide and tirzepatide remain the cheapest legitimate path to a GLP-1 molecule for cash-pay patients in 2026 — but the legal, commercial, and clinical landscape around them shifted in 2024–2025, and most consumer-facing pages haven't caught up. This guide reflects what's actually legal, available, and clinically defensible right now.
We verified the pharmacy partner of every program on this list against state board records, confirmed 503B outsourcing facility registrations through the FDA's public directory, ordered samples through anonymized accounts, and tested third-party potency-and-sterility certificates. Programs that wouldn't disclose their pharmacy partner are not on this page. Programs operating outside their state license are not on this page.
The 2026 ranking
Each program was verified against state-board records and tested through anonymous ordering. Click through to the provider page for the pharmacy partner name, license number, full pricing, and shipping turnaround. Every link is an affiliate link tracked through Impact Engine — see our disclosure.
| Rank | Provider | Best for | Sample type | Editor | Readers | Action |
|---|
How to evaluate a compounded GLP-1 program
Pharmacy partner is named, with a state license number
The single most important factor: the program tells you which pharmacy is preparing the medication, and that pharmacy holds a current license with the state board where it operates. Every state board of pharmacy in the U.S. publishes a public license lookup. A program that won't name its pharmacy partner is not a program we recommend. The same applies to 503B outsourcing facilities — those are FDA-registered and the registration is public.
Third-party testing certificates available
Reputable 503A pharmacies test every batch for sterility, identity, and potency. 503B outsourcing facilities are subject to current Good Manufacturing Practices and the testing is more rigorous. Better consumer programs make these certificates available on request — at minimum a Certificate of Analysis showing potency tested against the labeled concentration. Certificates that don't name the testing lab or that show generic ranges instead of specific values are red flags.
Clinically-justified individual prescription, not bulk-prep
Post-shortage compounding is supposed to be done against an individual patient prescription with a clinical justification, not as bulk preparation of the same formulation for everyone who signs up. Programs that offer one-size-fits-all formulations without genuine clinical individualization are operating in a legally murkier space than programs that show evidence of clinician-driven individualization (different concentrations, different titration schedules, different delivery formats).
Transparent pricing, no surprise add-ons
Better programs quote a single bundled price that includes the medication, consultation, syringes and supplies, sharps disposal, and shipping. Programs that quote a low monthly rate but charge separately for any of the above end up 15–20% more expensive at checkout. The first-month price you see on the homepage should match the first-month price you see at checkout.
Real clinician oversight, not a forwarding service
Every program on this list connects you with a board-certified prescribing clinician licensed in your state. The clinician — not an algorithm, not a sales rep — should be reviewing your intake, asking follow-up questions when warranted, and available for side-effect questions during therapy. Programs that hand off to the pharmacy immediately after a five-question form without any clinical interaction are not what licensed compounding looks like.
The post-shortage rules narrowed compounded GLP-1, they didn't end it — but they eliminated about half of the consumer-facing programs that existed in 2024.
The 2025 shortage-list change and what it actually means
When the FDA declared semaglutide off the shortage list in early 2025 and tirzepatide off in late 2024, a meaningful share of compounded GLP-1 commerce had to change. During the shortage, 503A pharmacies could prepare the molecule from bulk API at scale and against simplified prescriptions. Off the shortage list, that broad permission ended. What continues legally: clinician-led individual prescriptions for compounded preparations when there's a documented clinical justification — most often allergy or sensitivity to an inactive ingredient in the brand product, or a need for a non-standard dose or delivery format.
Reputable 503A pharmacies and 503B outsourcing facilities adapted their workflows. Reputable consumer-facing telehealth programs adapted their intake and clinical documentation. Programs that didn't adapt — programs that still operate as if the shortage was active — are at the highest risk of state board action and supply disruption. We've excluded those programs from this page.
FAQ: Compounded GLP-1
Is compounded semaglutide or tirzepatide the same as Ozempic or Mounjaro?
Same active ingredient, different product. Compounded GLP-1s are prepared at a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility against an individual patient prescription, at a pharmacy-determined concentration. They are not Ozempic, Wegovy, Mounjaro, or Zepbound — those are Novo Nordisk and Eli Lilly brand products with FDA-reviewed manufacturing and dosing. Clinically the molecule is the same; legally and commercially the products are distinct.
Is compounded GLP-1 still legal in 2026?
Yes, when prescribed by a licensed clinician for an individual patient and prepared at a licensed pharmacy. The legal landscape changed when FDA declared semaglutide off the shortage list in early 2025 and tirzepatide off in late 2024. That ended the broad permission for 503A pharmacies to mass-prepare these drugs from bulk API, but did not end clinically-justified individual prescriptions. Reputable 503A pharmacies and 503B outsourcing facilities continue to compound when there's an individual clinical justification.
What's the difference between a 503A and 503B pharmacy?
503A pharmacies prepare compounded medications against individual patient prescriptions, regulated primarily by state boards of pharmacy. 503B outsourcing facilities prepare larger batches, are voluntarily registered with the FDA, and are subject to FDA inspection and current Good Manufacturing Practices (cGMP). 503B oversight is more rigorous; 503A flexibility allows for individualized formulations. Both are legitimate when properly licensed.
How do I verify a compounding pharmacy is licensed?
Every state board of pharmacy publishes a license lookup tool. Search by pharmacy name and verify the license is current. For 503B outsourcing facilities, the FDA maintains a public registered-facilities list. Reputable telehealth programs disclose their pharmacy partner by name and license number on request — programs that won't name their pharmacy partner are red flags.
How is compounded GLP-1 typically priced?
$179–$249 for month one, $249–$349 ongoing for compounded semaglutide. Compounded tirzepatide runs $249–$349 month one, $349–$499 ongoing. Pricing usually bundles the telehealth consult, the medication, supplies (syringes, alcohol pads, sharps disposal), and shipping. Programs that quote a low monthly rate but charge separately for shipping or supplies are usually 15–20% more expensive at checkout.
What are the risks specific to compounded GLP-1s?
Variable potency between batches and pharmacies (less of an issue at 503B facilities), no FDA review of the specific compounded preparation, and the legal risk that a state board could change posture. Reputable pharmacies test for sterility, identity, and potency. The clinical risk profile of the active ingredient itself is the same as the brand drug — same nausea, same constipation, same boxed warnings.
Can I use a manufacturer savings card with compounded GLP-1?
No. Novo Nordisk and Eli Lilly savings cards apply only to their branded products. Compounded preparations are not eligible. Compounded GLP-1 programs are typically cash-pay only, with no insurance coverage and no manufacturer copay assistance.
Will my insurance reimburse compounded GLP-1?
Almost never. Insurance plans cover FDA-approved branded medications with appropriate prior authorization. Compounded preparations are typically excluded from formularies, and most claims for compounded GLP-1 are denied. Some FSA and HSA accounts will reimburse compounded medications with a clinician's prescription on file — verify with your plan administrator.